Treatment of cancer and autoimmune disorders using nanopolymers of histone deacetylase inhibitors

Compositions are provided that include a histone deacetylase inhibitor (HDACi) encapsulated in and/or otherwise associated with a nanoparticle. In some embodiments, HDACi is romidepsin, vorinostat, belinostat, panobinostat, and/or chidamide. In some embodiments, the nanoparticle is a poly (D, L-lactide)-PEG-methyl ether (mPEG-PDLLA) nanopolymer. Also provided are methods for treating diseases, disorders and/or conditions associated with sensitivity to histone deacetylase inhibitors, such as, but not limited to, tumors and/or cancers; and methods of inhibiting the growth, proliferation and/or metastasis of a tumor and/or cancer associated with sensitivity to a histone deacetylase inhibitor by administering an effective amount of the composition disclosed herein, which may optionally comprise administering at least one additional therapeutically active agent, such as, but not limited to, a chemotherapeutic agent. 提供了包括包封在纳米颗粒中和/或以其他方式与纳米颗粒相关联的组蛋白脱乙酰酶抑制剂(HDACi)的组合物。在一些实施方式中，HDACi是罗米地辛、伏立诺他、贝利司他、帕比司他和/或西达本胺。在一些实施